Physician profile
James Browning
NPI 1508313867
$568.61
in general payments reported to CMS, 2019-2025
14 companies · $84.79 in 2025
The $84.79 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $89.13 · 2023: $152 · 2024: $243 · 2025: $84.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $157.93 | 2024-2025 | Airsupra, Farxiga |
| Dexcom, INC. | $75.73 | 2022-2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $69.04 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $45.55 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $32.65 | 2024 | |
| Lilly USA, LLC | $28.02 | 2022-2023 | Zepbound |
| Axsome Therapeutics, INC. | $26.17 | 2024 | Auvelity |
| Insulet Corporation | $26.14 | 2024 | Omnipod |
| Abbvie INC. | $25.54 | 2025 | |
| Novo Nordisk INC | $19.41 | 2023 | Tresiba, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $17.34 | 2022 | |
| Abbott Laboratories | $15.15 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.12 | 2022 | |
| Amgen INC. | $14.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Browning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.